title: PET/CT with 68Gallium-DOTA-peptides in NET: an overview.
abstract: In the present review article we presented the major technical innovations regarding the diagnosis of NET with PET/CT 68Ga-DOTA-peptides compounds over conventional radiologic and scintigraphic imaging, discussing both the different types of radiopharmaceuticals commercially available, trying to making a comparison on the possible advantages and drawbacks of these radiopharmaceuticals, and providing also some technical recommendations to the radiologists and nuclear physicians for using these new methodology in an appropriate manner in the clinical setting.
authors.affiliation: Department of Nuclear Medicine, Sant' Orsola-Malpighi University Hospital, Bologna, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Ambrosini
authors.forename: Davide
authors.initials: D
authors.lastname: Campana
authors.forename: Paola
authors.initials: P
authors.lastname: Tomassetti
authors.forename: Gaia
authors.initials: G
authors.lastname: Grassetto
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
mesh_terms: D005710:Gallium Radioisotopes; D006801:Humans; D064847:Multimodal Imaging; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: C504894:68Ga-DOTANOC; D005710:Gallium Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals